218450-02-3

Upstream product

• 218450-01-2 1-(3,4-difluorophenyl)-2-hydroxy-propan-1-one 

Downstream Products

• 218450-03-4 1-amino-1-(3,4-difluoro-phenyl)-propan-2-ol 
• 218450-04-5 [1-(3,4-difluorophenyl)-2-hydroxypropyl]carbamic acid tert-butyl ester 
• 218450-16-9 trans(+)-4-(3,4-Difluorophenyl)-5-methyl-2-oxo-oxazolidine-3-carboxylic acid {3-[4-(4-fluorophenyl)-piperidin-1-yl]propyl}amide 
• 218450-10-3 4(S)-(3,4-difluorophenyl)-5(S)-methyloxazolidin-2-one 

Relevant academic research and scientific papers

Combination therapy for the treatment of benign prostatic hyperplasia

This invention relates to combination therapy for the treatment of benign prostatic hyperplasia comprising an alpha-1a antagonist and an endothelin antagonist. More specifically, the use of a selective alpha-1a adrenergic receptor antagonist in combination with a subtype non-selective endothelin antagonist provides relief of lower urinary tract symptoms in patients with symptomatic prostatism or benign prostatic hyperplasia. This combination therapy improves lower urinary tract symptoms including increasing urine flow rate, decreasing residual urine volume and improving overall obstructive and irritative symptoms in patients with benign prostatic hyperplasia or symptomatic prostatism.

Oxazolidinones as alpha 1A receptor antagonists

This invention is directed to oxazolidinone compounds which are selective antagonists for human alpha 1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the alpha 1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.